![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Mycostatin, others[1] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682758 |
License data | |
Routes of administration | Topical, vaginal, by mouth |
Drug class | Polyene antifungal medication[1] |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 0% on oral ingestion |
Metabolism | None (not extensively absorbed) |
Elimination half-life | Dependent upon GI transit time |
Excretion | Fecal (100%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.014.317 |
Chemical and physical data | |
Formula | C47H75NO17 |
Molar mass | 926.107 g·mol−1 |
3D model (JSmol) | |
Melting point | 44–46 °C (111–115 °F) |
| |
| |
![]() ![]() |
Nystatin, sold under the brand name Mycostatin among others, is an antifungal medication.[1] It is used to treat Candida infections of the skin including diaper rash, thrush, esophageal candidiasis, and vaginal yeast infections.[1] It may also be used to prevent candidiasis in those who are at high risk.[1] Nystatin may be used by mouth, in the vagina, or applied to the skin.[1]
Common side effects when applied to the skin include burning, itching, and a rash.[1] Common side effects when taken by mouth include vomiting and diarrhea.[1] During pregnancy use in the vagina is safe while other formulations have not been studied in this group.[1] It works by disrupting the cell membrane of the fungal cells.[1]
Nystatin was discovered in 1950 by Rachel Fuller Brown and Elizabeth Lee Hazen.[2] It was the first polyene macrolide antifungal.[3] It is on the World Health Organization's List of Essential Medicines.[4] It is available as a generic medication.[1] It is made from the bacterium Streptomyces noursei.[2] In 2021, it was the 233rd most commonly prescribed medication in the United States, with more than one million prescriptions.[5][6]